A surprise interim trial miss in ivonescimab’s closely watched Harmoni-3 trial has sent Summit Therapeutics’ shares tumbling, ...
Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing ...
As Merck & Co., Bristol Myers Squibb and Pfizer have hopped on the PD-(L)1xVEGF bispecific bandwagon, the question becomes how far the fanfare will spread. It’s more than just existing PD-1/L1 players ...
Breadth of physician-driven research underscores emerging trends in oncology as three abstracts are accepted at ASCO 2026: ...
DUBLIN--(BUSINESS WIRE)--The "PD-1 x VEGF and PD-L1 x VEGF Bispecific Antibodies: A Business, Pipeline And Competitor Analysis From An Industry Perspective" report has been added to ResearchAndMarkets ...
With Bristol Myers Squibb (BMS) now rolling out the SC version of rival nivolumab (Opdivo Qvantig), the shift from 30-minute intravenous (IV) infusion to 5-minute SC injection could be one of the most ...
Association of HIPEC response in ovarian cancer with PI3K/RAS/Notch gene signatures: A whole transcriptomic analysis of U.S. and French HIPEC treated ovarian cancer patients. This is an ASCO Meeting ...
While Merck’s PD-1/VEGF asset appears to match the performance of Summit Therapeutics’ ivonescimab, the pharma’s Phase 1/2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results